ATNM - CONSENSUS CO - Actinium Pharmaceuticals

Actinium Pharmaceuticals (ATNM) relies heavily on external contractors for the production of radiopharmaceuticals to avoid isotope shortages. This price chart helps track the dynamics of the asset, which has a value of 3.69. The business focuses on the rollout of Iomab-B for bone marrow transplant preparation. These activities are not subject to seasonal fluctuations or economic cycles, as the project's success depends on the results of medical trials.

This indicator represents the weighted average expected value of the asset, aggregating professional analyst forecasts to identify points of fundamental business revaluation. For Actinium Pharmaceuticals (ATNM), the consensus target price reflects market expectations regarding the outcomes of clinical trials for radiotherapeutic drugs, where any trend shifts signal a revision in the quality of promising biotechnological assets.